Sentry BioPharma Services ApS: Financial statements 2023
CVR: 41330619
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Sentry BioPharma Services ApS (CVR 41330619) has filed annual accounts for 2023. In 2023, the company reported a net result of DKK -3,614,910 compared with DKK -2,818,910 the year before. Equity in the 2023 report amounted to DKK -7,814,368.
- Profit/Loss
- DKK -3,614,910
- Equity
- DKK -7,814,368
- Total Assets
- DKK 3,573,623
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | -3.6 mio. | -7.8 mio. | - |
| 2022 | - | - | -2.8 mio. | -4.2 mio. | - |
| 2021 | - | - | -1.1 mio. | -1.4 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Sentry BioPharma Services ApS has published its annual report for 2022. The net result was DKK -2,818,910.
As of February 14, 2023, William Maxwell Tuttle is registered as director of Sentry BioPharma Services ApS.
About Sentry BioPharma Services ApS
Sentry BioPharma Services ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2020. The company is registered under the industry Oplagring og opbevaring. The management consists of Timothy Jon Mitchell and William Maxwell Tuttle. The company is owned by Sentry BioPharma Services, Inc.. The company has 1 employee (2026). In 2025, the company reported a net result of DKK -537,511 compared with DKK -3,275,518 the year before. Equity in the 2025 report amounted to DKK -11,627,396.